ADVERTISEMENT
ADVERTISEMENT

Cardiology

D. Waters, L. Higginson, P. Gladstone, B. Kimball, M. Le May, S.J. Boccuzzi, J. Lesp}rance, Canadian Coronary Atherosclerosis Intervention Trial Study Group, "Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by seral quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial," Circulation, 89:959-68, 1994. (Cited in nearly 60 publications as of February 1996) Comments by David Waters, Hartford Hospit

Karen Young Kreeger

D. Waters, L. Higginson, P. Gladstone, B. Kimball, M. Le May, S.J. Boccuzzi, J. Lesp}rance, Canadian Coronary Atherosclerosis Intervention Trial Study Group, "Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by seral quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial," Circulation, 89:959-68, 1994. (Cited in nearly 60 publications as of February 1996)

Comments by David Waters, Hartford Hospital, Connecticut

Cholesterol-lowering drugs have become a multimillion-dollar industry over the past decade. Medications such as lovastatin, which inhibits the action of the enzyme HMG-CoA reductase, are widely prescribed by physicians for people with extremely high cholesterol. Yet how these drugs affect coronary atherosclerosis-a condition directly linked to abnormally high cholesterol levels-had not been fully characterized by clinicians.

Dave Waters
HEART SMART: Results from a cholesterol-drug trial headed by David Waters show benefits for many groups.
This paper describes the first set of findings from...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT